BAYER AG

NUBEQA® (darolutamide) plus ADT showed a 46% reduction in risk of progression or death in the Phase III ARANOTE trial for metastatic hormone-sensitive prostate cancer (mHSPC), with no new safety signals observed. Results were published in The Journal of Clinical Oncology.

NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) in the Phase III ARANOTE trial for metastatic hormone-sensitive prostate cancer, reducing the risk of progression or death by 46% (HR 0.54; 95% CI 0.41-0.71; P<0.0001) compared to placebo plus ADT. The results were consistent with NUBEQA's established safety profile, with no new safety signals observed.

We've detected unusual activity from your computer network. To continue, click the box below to confirm you're not a robot.

At ESMO Congress 2024, updated Phase III IMbrave050 trial data showed no significant RFS benefit for Tecentriq + Avastin as adjuvant therapy in high-risk HCC, despite earlier interim analysis benefits. Ongoing trials like CheckMate 9DX and KEYNOTE-93 aim to evaluate monotherapy options for HCC, with potential market impacts by 2030.

Preoperative chemoradiotherapy did not improve survival over perioperative chemotherapy alone in resectable gastric and gastroesophageal junction adenocarcinoma, according to TOPGEAR data. Median overall survival was 46.4 months vs 49.4 months, with no significant differences in progression-free survival. However, preoperative chemoradiotherapy significantly improved pathological outcomes, including complete response rates and tumor downstaging.

Bayer will present new prostate cancer data, including a Phase III ARANOTE trial analysis of NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC), at the ESMO Congress 2024 in Barcelona.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Personalized medicine market to reach $900.67 Bn by 2030, driven by cancer therapies and genetic tech. North America leads, emphasizing personalized nutrition and expanding therapeutic applications.

India's 'BioE3' policy aims to drive biotech innovation through biomanufacturing, bio-AI hubs, and bio-foundries, focusing on precision therapeutics and biologics. Organ-on-chip technology, valued at $1.4 billion by 2032, offers a more accurate drug testing platform, reducing animal use and speeding up drug development. Investments and collaborations globally highlight the technology's potential, while India faces challenges in interdisciplinary collaboration and regulatory navigation to fully utilize this technology.

Bayer presents OASIS 3 study results at TMS 2024, showing elinzanetant's efficacy in reducing moderate to severe vasomotor symptoms (VMS) associated with menopause, with sustained safety over 52 weeks. Elinzanetant, a dual neurokinin-1 and -3 receptor antagonist, met primary and secondary endpoints, maintaining VMS reductions and improving sleep disturbances and quality of life. Bayer plans to seek marketing authorizations globally.